1. Home
  2. JMM vs RLMD Comparison

JMM vs RLMD Comparison

Compare JMM & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JMM
  • RLMD
  • Stock Information
  • Founded
  • JMM 1988
  • RLMD 2004
  • Country
  • JMM United States
  • RLMD United States
  • Employees
  • JMM N/A
  • RLMD N/A
  • Industry
  • JMM Trusts Except Educational Religious and Charitable
  • RLMD Biotechnology: Pharmaceutical Preparations
  • Sector
  • JMM Finance
  • RLMD Health Care
  • Exchange
  • JMM Nasdaq
  • RLMD Nasdaq
  • Market Cap
  • JMM 59.8M
  • RLMD 52.8M
  • IPO Year
  • JMM N/A
  • RLMD N/A
  • Fundamental
  • Price
  • JMM $6.43
  • RLMD $1.59
  • Analyst Decision
  • JMM
  • RLMD Buy
  • Analyst Count
  • JMM 0
  • RLMD 3
  • Target Price
  • JMM N/A
  • RLMD $5.00
  • AVG Volume (30 Days)
  • JMM 16.1K
  • RLMD 1.6M
  • Earning Date
  • JMM 01-01-0001
  • RLMD 11-06-2025
  • Dividend Yield
  • JMM 5.44%
  • RLMD N/A
  • EPS Growth
  • JMM N/A
  • RLMD N/A
  • EPS
  • JMM N/A
  • RLMD N/A
  • Revenue
  • JMM N/A
  • RLMD N/A
  • Revenue This Year
  • JMM N/A
  • RLMD N/A
  • Revenue Next Year
  • JMM N/A
  • RLMD N/A
  • P/E Ratio
  • JMM N/A
  • RLMD N/A
  • Revenue Growth
  • JMM N/A
  • RLMD N/A
  • 52 Week Low
  • JMM $5.29
  • RLMD $0.24
  • 52 Week High
  • JMM $6.10
  • RLMD $3.98
  • Technical
  • Relative Strength Index (RSI)
  • JMM 58.73
  • RLMD 74.57
  • Support Level
  • JMM $6.29
  • RLMD $1.44
  • Resistance Level
  • JMM $6.52
  • RLMD $1.72
  • Average True Range (ATR)
  • JMM 0.08
  • RLMD 0.24
  • MACD
  • JMM 0.01
  • RLMD 0.05
  • Stochastic Oscillator
  • JMM 62.00
  • RLMD 86.90

About JMM Nuveen Multi-Market Income Fund (MA)

Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities including, but not limited to residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Share on Social Networks: